Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19.
作者信息
Ménard Timothé
机构信息
F. Hoffmann-La Roche, Basel, Switzerland.
出版信息
Ther Innov Regul Sci. 2021 May;55(3):631-632. doi: 10.1007/s43441-021-00281-0. Epub 2021 Mar 22.
Abstract
摘要
相似文献
1
Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19.
Ther Innov Regul Sci. 2021 May;55(3):631-632. doi: 10.1007/s43441-021-00281-0. Epub 2021 Mar 22.
2
New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19 : In Responding to a Global Health Crisis, Industry is Discovering New, Efficient Ways of Meeting Objectives.
Ther Innov Regul Sci. 2021 Mar;55(2):463-466. doi: 10.1007/s43441-020-00239-8. Epub 2020 Nov 25.
3
Letter to the Editor: The economic and mental health costs of COVID-19 to immigrants.
J Psychiatr Res. 2020 Sep;128:23-24. doi: 10.1016/j.jpsychires.2020.06.003. Epub 2020 Jun 2.
4
Response to Letter to Editor Related to What Industrial Categories are Workers at Excess Risk of Filing a Covid-19 Workers' Compensation Claim? A Study Conducted in 11 Midwestern U.S. States.
J Occup Environ Med. 2022 Jan 1;64(1):e37-e38. doi: 10.1097/JOM.0000000000002400.
5
Emerging pulmonary histopathological findings in COVID-19 patients- a letter to the editor in response to Grosse et al. 2020.
Cardiovasc Pathol. 2021 Mar-Apr;51:107302. doi: 10.1016/j.carpath.2020.107302. Epub 2020 Nov 3.
6
Letter to the editor: More data on vaccine efficacy/effectiveness of COVID-19 vaccines against asymptomatic SARS-CoV-2 infection.
Euro Surveill. 2021 Sep;26(35). doi: 10.2807/1560-7917.ES.2021.26.35.2100826.
7
Response to the Letter to the Editor Regarding "Serologic Survey of IgG Against SARS-CoV-2 Among Hospital Visitors Without a History of SARS-CoV-2 Infection in Tokyo, 2020-2021".
J Epidemiol. 2023 Feb 5;33(2):109. doi: 10.2188/jea.JE20220202. Epub 2022 Nov 11.
8
Learning From Agility, Partnership and Innovation During the Covid-19 Pandemic: A Perspective From Industry.
Front Cell Infect Microbiol. 2022 Feb 17;12:838565. doi: 10.3389/fcimb.2022.838565. eCollection 2022.
9
Letter to the Editor Regarding "Pulmonary Embolism Prophylaxis in Patients With COVID-19: an Emerging Issue", Heart Lung Circ. 2021;30(10):1435-41.
Heart Lung Circ. 2022 Mar;31(3):e31. doi: 10.1016/j.hlc.2021.10.008. Epub 2021 Nov 4.
10
Letter to editor: Alimentary system is directly attacked by SARS-COV-2 and further prevents immune dysregulation caused by COVID-19.
Int J Clin Pract. 2021 Aug;75(8):e14049. doi: 10.1111/ijcp.14049.
引用本文的文献
1
Clinical Quality in Cancer Research: Strategy to Assess Data Integrity of Germline Variants Inferred from Tumor-Only Testing Sequencing Data.
Pharmaceut Med. 2021 Jul;35(4):225-233. doi: 10.1007/s40290-021-00399-4. Epub 2021 Aug 26.
2
Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group.
CPT Pharmacometrics Syst Pharmacol. 2021 Aug;10(8):799-803. doi: 10.1002/psp4.12677. Epub 2021 Jul 11.
3
Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development.
Ther Innov Regul Sci. 2021 Sep;55(5):1066-1074. doi: 10.1007/s43441-021-00308-6. Epub 2021 May 27.
本文引用的文献
1
New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19 : In Responding to a Global Health Crisis, Industry is Discovering New, Efficient Ways of Meeting Objectives.
Ther Innov Regul Sci. 2021 Mar;55(2):463-466. doi: 10.1007/s43441-020-00239-8. Epub 2020 Nov 25.
2
Leveraging analytics to assure quality during the Covid-19 pandemic - The COVACTA clinical study example.
Contemp Clin Trials Commun. 2020 Dec;20:100662. doi: 10.1016/j.conctc.2020.100662. Epub 2020 Oct 9.
3
Harnessing the Power of Quality Assurance Data: Can We Use Statistical Modeling for Quality Risk Assessment of Clinical Trials?
Ther Innov Regul Sci. 2020 Sep;54(5):1227-1235. doi: 10.1007/s43441-020-00147-x. Epub 2020 Mar 30.
Zotero 插件